• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies.

作者信息

Bogenberger James M, Delman Devora, Hansen Nanna, Valdez Riccardo, Fauble Veena, Mesa Ruben A, Tibes Raoul

机构信息

Department of Hematology and Oncology, Mayo Clinic , Scottsdale, AZ , USA.

出版信息

Leuk Lymphoma. 2015 Jan;56(1):226-9. doi: 10.3109/10428194.2014.910657. Epub 2014 Jun 17.

DOI:10.3109/10428194.2014.910657
PMID:24707940
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4331188/
Abstract
摘要

相似文献

1
Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies.BCL-2家族抑制剂ABT-199和ABT-737与5-氮杂胞苷联合用于髓系恶性肿瘤的体外活性
Leuk Lymphoma. 2015 Jan;56(1):226-9. doi: 10.3109/10428194.2014.910657. Epub 2014 Jun 17.
2
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.BCL-2 家族蛋白作为 5-氮杂胞苷增敏靶点及髓系恶性肿瘤反应的决定因素。
Leukemia. 2014 Aug;28(8):1657-65. doi: 10.1038/leu.2014.44. Epub 2014 Jan 23.
3
ABT-199 partners with azacitidine to contest myeloid malignancies.ABT-199与阿扎胞苷联合用于对抗髓系恶性肿瘤。
Leuk Lymphoma. 2015 Jan;56(1):8-9. doi: 10.3109/10428194.2014.919638. Epub 2014 Jul 15.
4
Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.Bcl-2磷酸化通过阻碍直接结合，赋予慢性淋巴细胞白血病细胞对BH3模拟物ABT-737、ABT-263和ABT-199的抗性。
Br J Pharmacol. 2016 Feb;173(3):471-83. doi: 10.1111/bph.13370. Epub 2016 Jan 16.
5
Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.凋亡抑制蛋白 MCL-1 和 BCL-2 过表达对 MLL-AF9 AML 小鼠发病机制及治疗的影响。
Cell Death Differ. 2019 Jul;26(7):1316-1331. doi: 10.1038/s41418-018-0209-1. Epub 2018 Nov 23.
6
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.ABT-199 选择性抑制 BCL-2 导致急性髓系白血病的靶细胞死亡。
Cancer Discov. 2014 Mar;4(3):362-75. doi: 10.1158/2159-8290.CD-13-0609. Epub 2013 Dec 17.
7
Quantitative assessment of the sensitivity of dormant AML cells to the BAD mimetics ABT-199 and ABT-737.对休眠急性髓系白血病细胞对BAD模拟物ABT-199和ABT-737敏感性的定量评估。
Leuk Lymphoma. 2018 Oct;59(10):2447-2453. doi: 10.1080/10428194.2018.1434884. Epub 2018 Feb 12.
8
Allosteric modulation of sigma receptors by BH3 mimetics ABT-737, ABT-263 (Navitoclax) and ABT-199 (Venetoclax).BH3 模拟物 ABT-737、ABT-263（Navitoclax）和 ABT-199（Venetoclax）对 sigma 受体的别构调节。
Pharmacol Res. 2019 Apr;142:87-100. doi: 10.1016/j.phrs.2019.01.040. Epub 2019 Feb 3.
9
Clinically relevant interactions of anti-apoptotic Bcl-2 protein inhibitors with ABC transporters.抗凋亡Bcl-2蛋白抑制剂与ABC转运蛋白的临床相关相互作用。
Pharmazie. 2017 Dec 1;72(12):751-758. doi: 10.1691/ph.2017.7696.
10
Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.同时抑制 DNA 甲基转移酶和 BCL-2 蛋白功能可协同诱导急性髓系白血病细胞线粒体凋亡。
Ann Hematol. 2012 Dec;91(12):1861-70. doi: 10.1007/s00277-012-1537-8. Epub 2012 Aug 15.

引用本文的文献

1
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia.靶向凋亡的BH3模拟物：改变急性髓系白血病患者的治疗方式
Nat Rev Clin Oncol. 2025 Sep 1. doi: 10.1038/s41571-025-01068-0.
2
Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: a case report and literature review.鲁索替尼耐药的慢性期骨髓纤维化患者对维奈克拉、阿扎胞苷和鲁索替尼的持久反应：一例报告及文献综述
Front Oncol. 2025 Aug 8;15:1644661. doi: 10.3389/fonc.2025.1644661. eCollection 2025.
3
Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular Era.

本文引用的文献

1
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.BCL-2 家族蛋白作为 5-氮杂胞苷增敏靶点及髓系恶性肿瘤反应的决定因素。
Leukemia. 2014 Aug;28(8):1657-65. doi: 10.1038/leu.2014.44. Epub 2014 Jan 23.
2
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.ABT-199 选择性抑制 BCL-2 导致急性髓系白血病的靶细胞死亡。
Cancer Discov. 2014 Mar;4(3):362-75. doi: 10.1158/2159-8290.CD-13-0609. Epub 2013 Dec 17.
3
Mitochondria: gatekeepers of response to chemotherapy.
解析维奈托克耐药性：在分子时代探索HMA/维奈托克难治性急性髓系白血病的未来。
Cancers (Basel). 2025 May 7;17(9):1586. doi: 10.3390/cancers17091586.
4
Meta-analysis on the effectiveness and safety of venetoclax-based combination therapy with hypomethylation in acute myeloid leukemia.维奈克拉联合低甲基化治疗急性髓系白血病有效性和安全性的Meta分析
Eur J Med Res. 2025 Apr 26;30(1):330. doi: 10.1186/s40001-025-02571-x.
5
Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days.急性髓系白血病中维奈托克的给药方案：7天对比14天对比21天对比28天。
Blood Cancer J. 2025 Apr 3;15(1):56. doi: 10.1038/s41408-025-01270-4.
6
Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia.西达本胺联合CAG及维奈克拉-阿扎胞苷治疗新诊断老年急性髓系白血病的2期研究
Front Immunol. 2025 Feb 26;16:1525110. doi: 10.3389/fimmu.2025.1525110. eCollection 2025.
7
Inducing apoptosis in acute myeloid leukemia; mechanisms and limitations.诱导急性髓系白血病细胞凋亡：机制与局限性
Heliyon. 2024 Dec 19;11(1):e41355. doi: 10.1016/j.heliyon.2024.e41355. eCollection 2025 Jan 15.
8
Getting the right combination to break the epigenetic code.找到正确的组合来破解表观遗传密码。
Nat Rev Clin Oncol. 2025 Feb;22(2):117-133. doi: 10.1038/s41571-024-00972-1. Epub 2024 Dec 2.
9
Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia.基于维奈托克的急性髓系白血病联合治疗方案
Blood Cancer Discov. 2025 Jan 8;6(1):23-37. doi: 10.1158/2643-3230.BCD-24-0171.
10
Enhancement of the Sensitivity of the Acute Lymphoblastic Leukemia Cells to ABT-737 by Formononetin.芒柄花素增强急性淋巴细胞白血病细胞对ABT-737的敏感性
Int J Mol Cell Med. 2024;13(3):259-271. doi: 10.22088/IJMCM.BUMS.13.3.259.
线粒体：化疗反应的守门员。
Trends Cell Biol. 2013 Dec;23(12):612-9. doi: 10.1016/j.tcb.2013.08.003. Epub 2013 Sep 21.
4
BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.BCL-2 抑制作用靶向氧化磷酸化并选择性根除静止期人类白血病干细胞。
Cell Stem Cell. 2013 Mar 7;12(3):329-41. doi: 10.1016/j.stem.2012.12.013. Epub 2013 Jan 17.
5
Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.同时抑制 DNA 甲基转移酶和 BCL-2 蛋白功能可协同诱导急性髓系白血病细胞线粒体凋亡。
Ann Hematol. 2012 Dec;91(12):1861-70. doi: 10.1007/s00277-012-1537-8. Epub 2012 Aug 15.
6
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia.抗凋亡蛋白 Mcl-1 对于急性髓系白血病的发生和持续生长是必需的。
Genes Dev. 2012 Jan 15;26(2):120-5. doi: 10.1101/gad.182980.111.
7
Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells.BH3模拟物ABT-737对真性红细胞增多症红系前体细胞的作用。
Blood. 2009 Feb 12;113(7):1522-5. doi: 10.1182/blood-2008-03-143321. Epub 2008 Dec 5.
8
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.由死亡信号引发的线粒体决定细胞对抗凋亡BCL-2家族成员的依赖性。
Cancer Cell. 2006 May;9(5):351-65. doi: 10.1016/j.ccr.2006.03.027.
9
Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells.抗凋亡蛋白MCL-1在造血干细胞存活中的关键作用。
Science. 2005 Feb 18;307(5712):1101-4. doi: 10.1126/science.1106114.
10
Expression of Bcl-x in erythroid precursors from patients with polycythemia vera.真性红细胞增多症患者红系前体细胞中Bcl-x的表达
N Engl J Med. 1998 Feb 26;338(9):564-71. doi: 10.1056/NEJM199802263380902.